Why the MedAdvisor Ltd (ASX:MDR) share price is up 20% today

The share price of digital medication management company MedAdvisor Ltd (ASX: MDR) has risen 20% to 4.8 cents in morning trade following the announcement that it has signed a Co-Marketing and Licence Agreement with PDX Inc, a large U.S. pharmacy dispensing software company.

MedAdvisor provides individuals and carers a medication management platform via its mobile and web apps to assist them in monitoring the use and adherence of prescription medication. The rise in internet connected devices provides an opportunity to deliver a solution for the issue of noncompliance of prescribed medication. The company services over 1 million users across Australia with connections to approximately 50% of pharmacies and general practitioners.

U.S. expansion 

PDX is a provider of clinical software and specialist pharmacy solutions that services over 10,000 pharmacies in the U.S. The company’s market share represents approximately 15% of the total pharmacy market in the U.S. and is 10 times larger than the Australian pharmacy market. This is MedAdvisor’s first step towards its roll-out and commercialistion in the U.S. market with integration set to commence in the first half of FY19. The Licence Agreement is non-exclusive and will allow both parties access to and the usage of the other parties’ software to facilitate the integration. 

The agreement will enable MedAdvisor to provide a complete solution to pharmacies using PDX’s software to manage interactions with digital customers that includes ordering via the MedAdvisor app. The company is well funded with a cash balance of $10.8 million as at 30 March 2018 to meet the projected rise in expenditure in order to complete the integration. MedAdvisor also noted in this morning’s announcement that it has the capacity to continue to expand domestically in Australia and progress any international opportunities.

MedAdvisor is one of the more intriguing small cap stocks operating in the healthcare space on the Australian market. Other small cap healthcare companies with a lot of potential that investors should consider monitoring include breast screening technology company Volpara Health Technologies Ltd (ASX: VHT) and healthcare provider Zenitas Healthcare Ltd (ASX: ZNT).

4 Stocks for Building Wealth After 50

Renowned investor Scott Phillips just released a brand-new report detailing his 4 favourite stocks to buy right now.

And I don’t know about you, but I always pay attention when some of the best investors in the world give me a stock tip.

This is your chance to get in at the very beginning of what could prove to be very special investments.

Click here to get started today!

Motley Fool contributor Tim Katavic has no financial interest in any company mentioned. The Motley Fool Australia owns shares of and has recommended VOLPARA FPO NZ. The Motley Fool Australia has recommended MedAdvisor and Zenitas Healthcare Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The 5 mining stocks we’re recommending in 2019…

For decades, Australian mining companies have minted money for individual investors like you and me. But if you believe the pundits and talking heads on TV, those days are long gone. Finito! Behind us forever…

We say nothing could be further from the truth. To earn the really massive returns, you’ve got to fish where others aren’t fishing—and the mining sector could be primed for a resurgence. That’s why top Motley Fool analysts just revealed their exciting new research on 5 ASX miners they believe could help you profit in 2019 and beyond…


The best way we see to play the global zinc shortage… Our #1 favourite large-cap miner (hint: it’s not BHP)… one early-stage gold miner we think could hit the motherlode… Plus two more surprising companies you probably haven’t heard of yet!

For free access to our brand-new research, simply click here or the link below. But be warned, this research is available free for a limited time only, and we reserve the right to withdraw it at any time.

Click here for your FREE report!